Effect of Information About the Benefits and Harms of Mammography on Women's Decision Making (InforMa)
Primary Purpose
Breast Cancer Screening
Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Decision aid for breast cancer screening
Standard leaflet
Sponsored by

About this trial
This is an interventional health services research trial for Breast Cancer Screening focused on measuring breast cancer, screening, decision aid, informed choice, decisional conflict
Eligibility Criteria
Inclusion Criteria:
- Women aged 49-50 who - in 2-4 months - will be invited to participate for the first time in the EDBCP of the Institut Hospital del Mar d'Investigacions Mèdiques (IMIM, Barcelona), ICO-Hospitalet (Hospitalet de Llobregat), Lleida Health Region, and the Canary Islands.
- Women with low health literacy will be included
Exclusion Criteria:
- Previous history of breast cancer
- Difficulty speaking Spanish or Catalan
- Cognitive impairment to understand or complete the materials based on the interviewer judgment
Sites / Locations
- Lleida Biomedical Research Institute (IRBLLEIDA)
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Decision aid
Control
Arm Description
Women in the intervention arm will receive a leaflet with detailed information on the benefits (breast cancer mortality reduction, less intensive treatments) and harms (false positive results and overdiagnosis).
Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial exams of the EDBCP.
Outcomes
Primary Outcome Measures
Informed choice
The primary outcome is informed choice about breast screening (adequate knowledge, and consistency between attitudes and intentions). See Hersch 2015.
Secondary Outcome Measures
Breast screening attitudes
According to Hersch 2015
Breast screening intention
According to Hersch 2015
Decisional conflict
According to Hersch 2015
Confidence in the decision made
According to Hersch 2015
Anxiety about screening participation
According to Hersch 2015
Worry about breast cancer
According to Hersch 2015
Anticipated regret
According to Hersch 2015
Time perspective
According to Hersch 2015
Perceived importance of benefit/harms of screening
According to Hersch 2015
Perceived risk of breast cancer
According to Hersch 2015
Full Information
NCT ID
NCT03046004
First Posted
February 4, 2017
Last Updated
April 2, 2021
Sponsor
Institut de Recerca Biomèdica de Lleida
Collaborators
Hospital del Mar, Canary Islands Health Service, Institut Català d'Oncologia
1. Study Identification
Unique Protocol Identification Number
NCT03046004
Brief Title
Effect of Information About the Benefits and Harms of Mammography on Women's Decision Making
Acronym
InforMa
Official Title
The Effect of Receiving Information About the Benefits and Harms of Mammography Screening on Women's Decision Making
Study Type
Interventional
2. Study Status
Record Verification Date
April 2021
Overall Recruitment Status
Completed
Study Start Date
July 1, 2016 (Actual)
Primary Completion Date
September 14, 2017 (Actual)
Study Completion Date
June 20, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Institut de Recerca Biomèdica de Lleida
Collaborators
Hospital del Mar, Canary Islands Health Service, Institut Català d'Oncologia
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of this study is to assess the effect of receiving information about the benefits and harms of mammography screening on informed choice, decisional conflict, intention to participate in the Early Detection of Breast Cancer Program (EDBCP), and satisfaction. The primary outcome is informed choice about breast screening (adequate knowledge, and consistency between attitudes and intentions). The sample of participants is composed by 400 women from Catalonia and the Canary Islands (Spain) who will receive their first invitation to participate in the EDBCP of the Public Health Service in a period of 2-4 months.
Detailed Description
The selected women will receive a letter of invitation with information about the study. In the following 1-2 weeks they will receive a phone call to confirm that they have received the mailed letter and to assess the inclusion criteria. If they agree to participate in the study, they will be asked for informed consent. All the participants will receive a first questionnaire, the pre-intervention survey (10-15 minutes), via web or regular mail. Trained interviewers will collect the responses by phone for women who prefer this method. Once the pre-intervention survey is completed, women will receive the leaflet (intervention or control) via regular mail. Two weeks later, the participants will be contacted again to collect the post-intervention survey (15-20 minutes), via web or by phone. Participation in the mammographic exams of the EDBCP will be collected in the three-month period following the corresponding invitation letter.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer Screening
Keywords
breast cancer, screening, decision aid, informed choice, decisional conflict
7. Study Design
Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
400 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Decision aid
Arm Type
Experimental
Arm Description
Women in the intervention arm will receive a leaflet with detailed information on the benefits (breast cancer mortality reduction, less intensive treatments) and harms (false positive results and overdiagnosis).
Arm Title
Control
Arm Type
Active Comparator
Arm Description
Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial exams of the EDBCP.
Intervention Type
Other
Intervention Name(s)
Decision aid for breast cancer screening
Intervention Description
Women in the intervention arm will receive a leaflet with detailed information on the benefits (breast cancer mortality reduction, less intensive treatments) and harms (false positive results and overdiagnosis).
Intervention Type
Other
Intervention Name(s)
Standard leaflet
Intervention Description
Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial exams of the EDBCP.
Primary Outcome Measure Information:
Title
Informed choice
Description
The primary outcome is informed choice about breast screening (adequate knowledge, and consistency between attitudes and intentions). See Hersch 2015.
Time Frame
Two weeks after the intervention
Secondary Outcome Measure Information:
Title
Breast screening attitudes
Description
According to Hersch 2015
Time Frame
Two weeks after the intervention
Title
Breast screening intention
Description
According to Hersch 2015
Time Frame
Two weeks after the intervention and after being invited to be screened
Title
Decisional conflict
Description
According to Hersch 2015
Time Frame
Two weeks after the intervention
Title
Confidence in the decision made
Description
According to Hersch 2015
Time Frame
Two weeks after the intervention
Title
Anxiety about screening participation
Description
According to Hersch 2015
Time Frame
Two weeks after the intervention
Title
Worry about breast cancer
Description
According to Hersch 2015
Time Frame
Two weeks after the intervention
Title
Anticipated regret
Description
According to Hersch 2015
Time Frame
Two weeks after the intervention
Title
Time perspective
Description
According to Hersch 2015
Time Frame
Two weeks after the intervention
Title
Perceived importance of benefit/harms of screening
Description
According to Hersch 2015
Time Frame
Two weeks after the intervention
Title
Perceived risk of breast cancer
Description
According to Hersch 2015
Time Frame
Two weeks after the intervention
10. Eligibility
Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
49 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Women aged 49-50 who - in 2-4 months - will be invited to participate for the first time in the EDBCP of the Institut Hospital del Mar d'Investigacions Mèdiques (IMIM, Barcelona), ICO-Hospitalet (Hospitalet de Llobregat), Lleida Health Region, and the Canary Islands.
Women with low health literacy will be included
Exclusion Criteria:
Previous history of breast cancer
Difficulty speaking Spanish or Catalan
Cognitive impairment to understand or complete the materials based on the interviewer judgment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Montserrat Rué, PhD
Organizational Affiliation
Universitat de Lleida-IRBLLEIDA
Official's Role
Principal Investigator
Facility Information:
Facility Name
Lleida Biomedical Research Institute (IRBLLEIDA)
City
Lleida
ZIP/Postal Code
25198
Country
Spain
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
28145105
Citation
Toledo-Chavarri A, Rue M, Codern-Bove N, Carles-Lavila M, Perestelo-Perez L, Perez-Lacasta MJ, Feijoo-Cid M; InforMa Study Group. A qualitative study on a decision aid for breast cancer screening: Views from women and health professionals. Eur J Cancer Care (Engl). 2017 May;26(3). doi: 10.1111/ecc.12660. Epub 2017 Feb 1.
Results Reference
background
PubMed Identifier
30913217
Citation
Perez-Lacasta MJ, Martinez-Alonso M, Garcia M, Sala M, Perestelo-Perez L, Vidal C, Codern-Bove N, Feijoo-Cid M, Toledo-Chavarri A, Cardona A, Pons A, Carles-Lavila M, Rue M; with the InforMa Group. Effect of information about the benefits and harms of mammography on women's decision making: The InforMa randomised controlled trial. PLoS One. 2019 Mar 26;14(3):e0214057. doi: 10.1371/journal.pone.0214057. eCollection 2019.
Results Reference
background
PubMed Identifier
32173050
Citation
Pons-Rodriguez A, Martinez-Alonso M, Perestelo-Perez L, Garcia M, Sala M, Rue M; en nombre del grupo InforMa; El grupo InforMa esta formado por. [Informed choice in breast cancer screening: the role of education]. Gac Sanit. 2021 May-Jun;35(3):243-249. doi: 10.1016/j.gaceta.2020.01.002. Epub 2020 Mar 12. Spanish.
Results Reference
background
PubMed Identifier
25701273
Citation
Hersch J, Barratt A, Jansen J, Irwig L, McGeechan K, Jacklyn G, Thornton H, Dhillon H, Houssami N, McCaffery K. Use of a decision aid including information on overdetection to support informed choice about breast cancer screening: a randomised controlled trial. Lancet. 2015 Apr 25;385(9978):1642-52. doi: 10.1016/S0140-6736(15)60123-4. Epub 2015 Feb 18. Erratum In: Lancet. 2015 Apr 25;385(9978):1622.
Results Reference
result
PubMed Identifier
28899412
Citation
Carles M, Martinez-Alonso M, Pons A, Perez-Lacasta MJ, Perestelo-Perez L, Sala M, Vidal C, Garcia M, Toledo-Chavarri A, Codern N, Feijoo-Cid M, Romero A, Pla R, Soler-Gonzalez J, Castells X, Rue M; InforMa Group. The effect of information about the benefits and harms of mammography on women's decision-making: study protocol for a randomized controlled trial. Trials. 2017 Sep 12;18(1):426. doi: 10.1186/s13063-017-2161-7.
Results Reference
derived
Learn more about this trial
Effect of Information About the Benefits and Harms of Mammography on Women's Decision Making
We'll reach out to this number within 24 hrs